Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Breast cancer-related lymphedema and recurrence of breast cancer: Protocol for a prospective cohort study in China.

Tytuł:
Breast cancer-related lymphedema and recurrence of breast cancer: Protocol for a prospective cohort study in China.
Autorzy:
Zhuang L; Department of Rheumatology and Immunology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Chen Q; Center of Biostatistics, Design, Measurement and Evaluation, Department of Clinical Research Management, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Chen H; Department of Head and Neck Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Zheng X; Department of Head and Neck Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Liu X; Department of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Feng Z; Department of Head and Neck Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; Unit of Cancer Day Care, West China Hospital, Sichuan University, Chengdu, China.
Wu S; Department of Head and Neck Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Liu L; Department of Head and Neck Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Shen X; Department of Rheumatology and Immunology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Źródło:
PloS one [PLoS One] 2023 May 16; Vol. 18 (5), pp. e0285772. Date of Electronic Publication: 2023 May 16 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: San Francisco, CA : Public Library of Science
MeSH Terms:
Breast Neoplasms*/pathology
Breast Cancer Lymphedema*/etiology
Breast Cancer Lymphedema*/complications
Lymphedema*/epidemiology
Lymphedema*/etiology
Lymphedema*/diagnosis
Female ; Humans ; Cohort Studies ; Quality of Life ; Prospective Studies ; Neoplasm Recurrence, Local/epidemiology
References:
Br J Cancer. 2020 Jul;123(1):17-25. (PMID: 32362658)
JAMA. 2020 Dec 15;324(23):2396-2405. (PMID: 33320224)
Indian J Pediatr. 2012 Nov;79(11):1482-8. (PMID: 22562262)
Lancet Glob Health. 2019 Apr;7(4):e436-e447. (PMID: 30879508)
Gland Surg. 2018 Aug;7(4):379-403. (PMID: 30175055)
J Clin Oncol. 2022 Mar 20;40(9):1009-1026. (PMID: 35077194)
J Oncol Pract. 2019 Sep;15(9):e787-e797. (PMID: 31298966)
Nat Rev Dis Primers. 2019 Mar 28;5(1):22. (PMID: 30923312)
J Natl Compr Canc Netw. 2020 Apr;18(4):452-478. (PMID: 32259783)
J Clin Oncol. 2015 Nov 1;33(31):3608-14. (PMID: 26417002)
PLoS One. 2022 Sep 19;17(9):e0274570. (PMID: 36121834)
Ann Oncol. 2013 Oct;24 Suppl 6:vi7-23. (PMID: 23970019)
Front Oncol. 2023 Jan 19;13:1032749. (PMID: 36741020)
J Med Econ. 2023 Jan-Dec;26(1):254-261. (PMID: 36756852)
Ann Oncol. 2021 Dec;32(12):1475-1495. (PMID: 34678411)
Lancet Oncol. 2013 May;14(6):500-15. (PMID: 23540561)
Braz J Psychiatry. 2013 Oct-Dec;35(4):416-31. (PMID: 24402217)
Lymphology. 2020;53(1):3-19. (PMID: 32521126)
Lymphology. 2013 Sep;46(3):132-43. (PMID: 24645536)
Ann Surg. 2021 Jul 1;274(1):170-178. (PMID: 31348041)
JAMA Oncol. 2016 Aug 1;2(8):1049-55. (PMID: 27032109)
JAMA. 2022 Jan 4;327(1):41-49. (PMID: 34982119)
JAMA. 2022 Jun 14;327(22):2220-2230. (PMID: 35699706)
Support Care Cancer. 2020 Aug;28(8):3593-3603. (PMID: 32415386)
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):62-70. (PMID: 30165125)
JAMA Psychiatry. 2013 Dec;70(12):1363-71. (PMID: 24173618)
Ann Oncol. 2009 May;20 Suppl 4:10-4. (PMID: 19454421)
Lancet. 2011 Aug 27;378(9793):771-84. (PMID: 21802721)
Entry Date(s):
Date Created: 20230516 Date Completed: 20230518 Latest Revision: 20230615
Update Code:
20240105
PubMed Central ID:
PMC10187897
DOI:
10.1371/journal.pone.0285772
PMID:
37192209
Czasopismo naukowe
Introduction: The primary aim is to determine the factors associated with breast cancer-related lymphedema and to identify new associated factors for the recurrence of breast cancer and depression. The secondary objective is to investigate the incidence of breast cancer-related events (breast cancer-related lymphedema, recurrence of breast cancer, and depression). Finally, we want to explore and validate the complex relationship among multiple factors influencing breast cancer complications and breast cancer recurrence.
Patients and Methods: A cohort study of females with unilateral breast cancer will be conducted in West China Hospital between February 2023 and February 2026. Breast cancer survivors in the age range of 17-55 will be recruited before breast cancer surgery. We will recruit 1557 preoperative patients with a first invasive breast cancer diagnosis. Consenting breast cancer survivors will complete demographic information, clinicopathological factors, surgery information, baseline information, and a baseline depression questionnaire. Data will be collected at four stages: the perioperative stage, chemotherapy therapy stage, radiation therapy stage, and follow-up stage. Data including the incidence and correlation of breast cancer-related lymphedema, breast cancer recurrence, depression, and medical cost will be collected and computed through the four stages above. For every statistical analysis, the participants will be classified into two groups based on whether they develop secondary lymphedema. Incidence rates of breast cancer recurrence and depression will be calculated separately for groups. Multivariate logistic regression will be used to determine whether secondary lymphedema and other parameters can predict breast cancer recurrence.
Discussion: Our prospective cohort study will contribute to establishing an early detection program for breast cancer-related lymphedema and recurrence of breast cancer, which are both associated with poor quality of life and reduced life expectancy. Our study can also provide new insights into the physical, economic, treatment-related and mental burdens of breast cancer survivors.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2023 Zhuang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies